273 related articles for article (PubMed ID: 15207426)
1. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years.
Morgante L; Basile G; Epifanio A; Spina E; Antonini A; Stocchi F; Di Rosa E; Martino G; Marconi R; La Spina P; Nicita-Mauro V; Di Rosa AE
Arch Gerontol Geriatr Suppl; 2004; (9):291-6. PubMed ID: 15207426
[TBL] [Abstract][Full Text] [Related]
2. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease.
Di Rosa AE; Epifanio A; Antonini A; Stocchi F; Martino G; Di Blasi L; Tetto A; Basile G; Imbesi D; La Spina P; Di Raimondo G; Morgante L
Neurol Sci; 2003 Oct; 24(3):174-5. PubMed ID: 14598073
[TBL] [Abstract][Full Text] [Related]
3. Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease.
Alegret M; Valldeoriola F; Martí M; Pilleri M; Junqué C; Rumià J; Tolosa E
Mov Disord; 2004 Dec; 19(12):1463-9. PubMed ID: 15390065
[TBL] [Abstract][Full Text] [Related]
4. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
5. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
[TBL] [Abstract][Full Text] [Related]
6. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
[TBL] [Abstract][Full Text] [Related]
7. [Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: experience and recommendations].
Castaño B; Mateo D; Giménez-Roldán S
Neurologia; 2007 Apr; 22(3):133-7. PubMed ID: 17364250
[TBL] [Abstract][Full Text] [Related]
8. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
[TBL] [Abstract][Full Text] [Related]
9. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
Nyholm D; Constantinescu R; Holmberg B; Dizdar N; Askmark H
Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087
[TBL] [Abstract][Full Text] [Related]
10. [Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].
Pollak P; Champay AS; Gaio JM; Hommel M; Benabid AL; Perret J
Rev Neurol (Paris); 1990; 146(2):116-22. PubMed ID: 2320817
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study.
García Ruiz PJ; Sesar Ignacio A; Ares Pensado B; Castro García A; Alonso Frech F; Alvarez López M; Arbelo González J; Baiges Octavio J; Burguera Hernández JA; Calopa Garriga M; Campos Blanco D; Castaño García B; Carballo Cordero M; Chacón Peña J; Espino Ibáñez A; Gorospe Onisalde A; Giménez-Roldán S; Granés Ibáñez P; Hernández Vara J; Ibáñez Alonso R; Jiménez Jiménez FJ; Krupinski J; Kulisevsky Bojarsky J; Legarda Ramírez I; Lezcano García E; Martínez-Castrillo JC; Mateo González D; Miquel Rodríguez F; Mir P; Muñoz Fargas E; Obeso Inchausti J; Olivares Romero J; Olivé Plana J; Otermin Vallejo P; Pascual Sedano B; Pérez de Colosía Rama V; Pérez López-Fraile I; Planas Comes A; Puente Periz V; Rodríguez Oroz MC; Sevillano García D; Solís Pérez P; Suárez Muñoz J; Vaamonde Gamo J; Valero Merino C; Valldeoriola Serra F; Velázquez Pérez JM; Yáñez Baña R; Zamarbide Capdepon I
Mov Disord; 2008 Jun; 23(8):1130-6. PubMed ID: 18442107
[TBL] [Abstract][Full Text] [Related]
12. The duration of the motor response to apomorphine boluses is conditioned by the length of a prior infusion in Parkinson's disease.
Vaamonde J; Flores JM; Weisser R; Ibañez R; Obeso JA
Mov Disord; 2009 Apr; 24(5):762-5. PubMed ID: 19224589
[TBL] [Abstract][Full Text] [Related]
13. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
[TBL] [Abstract][Full Text] [Related]
14. [Sublingual administration of apomorphine in the treatment of motor fluctuations in Parkinson disease].
Durif F; Deffond D; Eschalier A; Tournilhac M
Rev Neurol (Paris); 1992; 148(10):610-4. PubMed ID: 1295055
[TBL] [Abstract][Full Text] [Related]
15. [Subcutaneous apomorphine in the treatment of Parkinson's disease].
Linazasoro G
Neurologia; 1994 Jan; 9(1):1-3. PubMed ID: 8161461
[TBL] [Abstract][Full Text] [Related]
16. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations.
van Laar T; Postma AG; Drent M
Parkinsonism Relat Disord; 2010 Jan; 16(1):71-2. PubMed ID: 19524477
[No Abstract] [Full Text] [Related]
17. Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.
Vaamonde J; Luquin MR; Obeso JA
Mov Disord; 1990; 5(3):260-2. PubMed ID: 2388647
[TBL] [Abstract][Full Text] [Related]
18. [Candidate patient for treatment with continuous apomorphine infusion].
Martí MJ; Kulisevsky J
Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.
Hughes AJ; Bishop S; Kleedorfer B; Turjanski N; Fernandez W; Lees AJ; Stern GM
Mov Disord; 1993 Apr; 8(2):165-70. PubMed ID: 8474483
[TBL] [Abstract][Full Text] [Related]
20. Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease.
Priano L; Albani G; Calderoni S; Baudo S; Lopiano L; Rizzone M; Astolfi V; Cavalli R; Gasco MR; Fraschini F; Bergamasco B; Mauro A
Neurol Sci; 2002 Sep; 23 Suppl 2():S99-100. PubMed ID: 12548362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
